# Denosumab in Subjects With Giant Cell Rich Tumors of Bone

> **NCT03605199** · PHASE2 · UNKNOWN · sponsor: **Leiden University Medical Center** · enrollment: 60 (estimated)

## Conditions studied

- Aneurysmal Bone Cysts
- Giant Cell Granuloma
- Osteoblastoma
- Chondroblastoma
- Chondromyxoid Fibroma

## Interventions

- **DRUG:** Denosumab

## Key facts

- **NCT ID:** NCT03605199
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-18
- **Primary completion:** 2021-06
- **Final completion:** 2023-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-08-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605199, "Denosumab in Subjects With Giant Cell Rich Tumors of Bone". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03605199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*